{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-003551","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-07-21T20:05:53+00:00","discovered_at":"2026-07-21T20:07:00.466893+00:00","generated_at":"2026-07-21T20:07:09.372716+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion shareholders approve 10M share authorized increase and warrant exercisability","bullets":["Meeting reconvened July 20, 2026 after July 13 adjournment due to lack of quorum.","Proposal 1 (warrant exercisability) approved with 93.3% in favor (214,091 votes for, 15,293 against).","Proposal 2 (authorized share increase) approved with 89.8% in favor (205,551 for, 23,382 against).","Authorized shares increased from 5,900,000 to 15,900,000 ordinary shares (par value $0.135).","Memorandum Amendment filed with Cayman Islands Registrar on July 21, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-003551","json":"https://secwatch.observer/filing/0001178913-26-003551.json","markdown":"https://secwatch.observer/filing/0001178913-26-003551.md","text":"https://secwatch.observer/filing/0001178913-26-003551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003551/0001178913-26-003551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003551/zk2635714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-21T20:07:09.372716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}